326 results on '"Thomas-Schoemann, A."'
Search Results
2. Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report
3. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection
4. Predictive factors associated with pemetrexed acute toxicity
5. Évaluation de la prise de médicaments en autonomie par les patients en hôpital de jour d’oncologie
6. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
7. Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients
8. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
9. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
10. Médecines complémentaires et cancer
11. Anticancéreux par voie orale – Liens ville-hôpital
12. Les auteurs
13. Predictive factors associated with pemetrexed acute toxicity
14. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences
15. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
16. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
17. Rôle du pharmacien dans l’évaluation du risque de prescription des anticoagulants oraux directs chez les patients atteints de cancer
18. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report
19. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma
20. Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France
21. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old
22. Drug interactions with solid tumour-targeted therapies
23. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study
24. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
25. ADAM9 expression promotes an aggressive lung adenocarcinoma phenotype
26. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
27. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
28. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
29. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
30. Rôle du pharmacien dans l’évaluation du risque de prescription des anticoagulants oraux directs chez les patients atteints de cancer
31. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients
32. The impact of body composition parameters on severe toxicity of nivolumab
33. Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS)
34. 1549P Pazopanib exposure in advanced soft tissue and bone sarcoma: A pharmacokinetic/pharmacodynamic analysis
35. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours
36. Soluble VEGFR-1: A new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?)
37. Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study
38. Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5e journée de pharmacologie des anti-tumoraux
39. Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
40. Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients
41. Chapitre 31 - Anticancéreux par voie orale – Liens ville-hôpital
42. PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTRE PROSPECTIVE STUDY.
43. Prevalence of Drug-Drug Interactions in Sarcoma Patients: Key Role of the Pharmacist Integration for Toxicity Risk Management
44. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
45. Médecines complémentaires et cancer
46. Les auteurs
47. Anticancéreux par voie orale – Liens ville-hôpital
48. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
49. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
50. Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.